160 related articles for article (PubMed ID: 32384445)
1. Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report.
Lee CH; Jeon SY; Yhim HY; Jang KY; Kwak JY
Medicine (Baltimore); 2020 May; 99(19):e19962. PubMed ID: 32384445
[TBL] [Abstract][Full Text] [Related]
2. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
3. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
[TBL] [Abstract][Full Text] [Related]
4. [Follicular lymphoma complicated with myelofibrosis and macroglobulinemia at initial presentation].
Kuroda H; Abe T; Jomen W; Yoshida M; Matsuno T; Sato M; Yamada M; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Murase K; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2068-73. PubMed ID: 24305541
[TBL] [Abstract][Full Text] [Related]
5. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Lee H; Basso IN; Kim DDH
Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous occurrence of chronic myelogenous leukemia and non-Hodgkin lymphoma at diagnosis.
Acar H; Ecirli S; Gündoğan F; Bulay O; Acar A
Cancer Genet Cytogenet; 1999 Jan; 108(2):171-4. PubMed ID: 9973949
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
8. Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report.
Pirozzi A; Cartenì G; Scagliarini S; Fusco M; Riccardi F
Medicine (Baltimore); 2019 Mar; 98(11):e14805. PubMed ID: 30882658
[TBL] [Abstract][Full Text] [Related]
9. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
10. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
11. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
12. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
13. [Hematological malignancies].
Usui N
Gan To Kagaku Ryoho; 2007 Mar; 34(3):358-66. PubMed ID: 17353625
[TBL] [Abstract][Full Text] [Related]
14. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
15. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Yang QX; Pei XJ; Tian XY; Li Y; Li Z
Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
[TBL] [Abstract][Full Text] [Related]
16. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
[TBL] [Abstract][Full Text] [Related]
17. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
19. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
